Details of Disease

General Information of Disease (ID: DISQX1LF)

• Disease Name: Plaque psoriasis
• Disease Class: EA90: Psoriasis
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISQX1LF: Plaque psoriasis
• ICD Code:
  ICD-11: ICD-11: EA90.0
  ICD-10: ICD-10: L40.0
  ICD-9: ICD-9: 696
  Expand ICD-9: 696

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 13 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bimekizumab	DMR9TF1	Approved	NA	[1]
Brodalumab	DMASDQ6	Approved	Monoclonal antibody	[2]
CNTO-1959	DMPC2QY	Approved	Antibody	[3]
Deucravacitinib	DMAR1YS	Approved	NA	[4]
Infliximab	DMH7OIA	Approved	Antibody	[5]
Ixekizumab	DMXW92T	Approved	Monoclonal antibody	[6]
Risankizumab	DMM32GT	Approved	NA	[7]
Secukinumab	DMYXT2U	Approved	Monoclonal antibody	[8]
Spesolimab	DM9FZYT	Approved	NA	[9]
Tapinarof	DMRPI2Q	Approved	NA	[10]
Tildrakizumab	DMLW9HG	Approved	Antibody	[11]
Ustekinumab	DMHTYK3	Approved	Antibody	[12]
LEO 80185	DM7XLJU	Phase 4	Small molecular drug	[9]

This Disease is Treated as An Indication in 56 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
122-0551 foam	DMRL2YX	Phase 3	NA	[13]
ABP 501	DM2J4YB	Phase 3	Antibody	[13]
ABP 654	DM0GXWT	Phase 3	Monoclonal antibody	[14]
ABT-874	DMYHSO2	Phase 3	NA	[15]
ARQ-151	DML61S4	Phase 3	Small molecular drug	[9]
AVT02	DM4CWNN	Phase 3	Antibody	[16]
CHS-0214	DM11R0Z	Phase 3	NA	[13]
CHS-1420	DM3RGLW	Phase 3	NA	[13]
DFD-06	DM0KHNC	Phase 3	NA	[13]
GP-2017	DMR670F	Phase 3	NA	[13]
IB-MECA	DM9G5XD	Phase 3	Small molecular drug	[9]
IDP-122	DM3A701	Phase 3	NA	[13]
M-518101	DMZ6VD5	Phase 3	NA	[13]
MABp1	DM8D13S	Phase 3	NA	[9]
MC2-01 PAD cream	DMNADRJ	Phase 3	NA	[9]
MK-3222	DMQBF7O	Phase 3	Antibody	[13]
MSB11022	DMXSDL0	Phase 3	NA	[9]
SB2	DMS1PFA	Phase 3	NA	[13]
Sernivo	DMUOFM4	Phase 3	NA	[9]
Spermidine	DMVJNFI	Phase 3	Small molecular drug	[13]
Vanadate	DMQL0KF	Phase 3	Small molecular drug	[13]
Xaliproden	DM1JCW8	Phase 3	Small molecular drug	[13]
ARQ-154	DMYEIOH	Phase 2	Small molecular drug	[17]
BCX-3408	DMRSG31	Phase 2	Small molecular drug	[18]
BI-730357	DMAS9PU	Phase 2	Small molecular drug	[19]
BMX-010	DM6CJ12	Phase 2	NA	[9]
CJM112	DMTSVJM	Phase 2	NA	[9]
CT 327	DMQXL1T	Phase 2	NA	[13]
GR-MD-02	DM9QF65	Phase 2	Protein	[13]
GSK2981278	DM25YLM	Phase 2	NA	[13]
GSK2982772	DM7HNFV	Phase 2	NA	[9]
IDP-118	DM0MPMN	Phase 2	NA	[13]
Impoyz	DMB1N6P	Phase 2	NA	[9]
IR502	DMW2IF9	Phase 2	NA	[13]
JNJ-38518168	DM9UMIO	Phase 2	NA	[13]
JTE-051	DM2LBHN	Phase 2	NA	[9]
LEO-32731	DMZ6Y0T	Phase 2	NA	[9]
LYC-30937	DMP05GL	Phase 2	NA	[9]
Mical (1)	DMPPWMZ	Phase 2	NA	[9]
MT203	DM7I0MT	Phase 2	Monoclonal antibody	[20]
PF-06700841	DMMGSFV	Phase 2	NA	[9]
PF-06826647	DM5H8V1	Phase 2	Small molecular drug	[21]
PF-3893787	DMC2FAL	Phase 2	Small molecular drug	[13]
SNA-120	DMPN314	Phase 2	NA	[9]
XP-23829	DMELUYN	Phase 2	NA	[9]
Dalazatide	DMJ1NG4	Phase 1b/2a	NA	[13]
ESR0114	DMUNM4D	Phase 1/2	NA	[9]
SHR-1314	DMADNY3	Phase 1/2	NA	[9]
ABP-710	DMIMVBQ	Phase 1	NA	[9]
AZD0284	DMHBEKM	Phase 1	NA	[9]
GSK2831781	DMC47M9	Phase 1	NA	[9]
JTE-451	DM01JU8	Phase 1	NA	[9]
ONS-3010	DMVMZ8M	Phase 1	NA	[9]
PF-06763809	DMQUNRW	Phase 1	NA	[9]
SM04755	DM491NI	Phase 1	NA	[9]
NIA-114	DM3ADQW	Clinical trial	NA	[13]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GP2015	DMVYFTQ	Application submitted	NA	[13]
Jemdel	DMJ0IDB	Application submitted	NA	[9]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761151
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [3] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [4] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214958.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5004).
• [6] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215272.
• [11] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6885).
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] ClinicalTrials.gov (NCT04607980) A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. U.S.National Institutes of Health.
• [15] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [16] ClinicalTrials.gov (NCT03849404) A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira? in Patients With Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS). U.S.National Institutes of Health.
• [17] ClinicalTrials.gov (NCT04128007) Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT01407874) A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT03835481) A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT02393378) Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate. U.S. National Institutes of Health.
• [21] ClinicalTrials.gov (NCT03210961) A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis. U.S. National Institutes of Health.